Patents Assigned to Yecuris Corporation
  • Fumarylacetoacetate hydrolase (FAH)-deficient and immunodeficient rats and uses thereof
    Patent number: 11793178
    Abstract: Described herein are rats with a hepatic deficiency comprising decreased function, activity, or expression of an enzyme in the tyrosine catabolic pathway (such as fumarylacetoacetate hydrolase), and methods of using the same for in vivo engraftment and expansion of heterologous hepatocytes, such as human hepatocytes, analysis of human liver disease, and analysis of xenobiotics. Also disclosed is the use of immunodeficient rats for the engraftment and expansion of heterologous hepatocytes.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: October 24, 2023
    Assignee: Yecuris Corporation
    Inventors: John R. Bial, Elizabeth M. Wilson, Aron M. Geurts
  • Fumarylacetoacetate hydrolase (Fah)-deficient and immunodeficient rats and uses thereof
    Patent number: 10470445
    Abstract: Described herein are rats with a hepatic deficiency comprising decreased function, activity, or expression of an enzyme in the tyrosine catabolic pathway (such as fumarylacetoacetate hydrolase), and methods of using the same for in vivo engraftment and expansion of heterologous hepatocytes, such as human hepatocytes, analysis of human liver disease, and analysis of xenobiotics. Also disclosed is the use of immunodeficient rats for the engraftment and expansion of heterologous hepatocytes.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: November 12, 2019
    Assignee: Yecuris Corporation
    Inventors: John R. Bial, Elizabeth M. Wilson, Aron M. Geurts
  • FUMARYLACETOACETATE HYDROLASE (FAH)-DEFICIENT AND IMMUNODEFICIENT RATS AND USES THEREOF
    Publication number: 20140373187
    Abstract: Described herein are rats with a hepatic deficiency comprising decreased function, activity, or expression of an enzyme in the tyrosine catabolic pathway (such as fumarylacetoacetate hydrolase), and methods of using the same for in vivo engraftment and expansion of heterologous hepatocytes, such as human hepatocytes, analysis of human liver disease, and analysis of xenobiotics. Also disclosed is the use of immunodeficient rats for the engraftment and expansion of heterologous hepatocytes.
    Type: Application
    Filed: August 24, 2012
    Publication date: December 18, 2014
    Applicant: Yecuris Corporation
    Inventors: John R. Bial, Elizabeth M. Wilson, Aron M. Geurts